On May, 4 Analysts See $-0.30 EPS for CytomX Therapeutics, Inc. (CTMX)

May 3, 2018 - By Gregory Tomko

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Corporate Logo

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is expected to publish earnings on May, 4., as reported by RTT. Analysts forecast 30.43 % diference or $-0.30 from the $-0.23 EPS from 2017. -1,600.00 % negative EPS growth is what analysts predict. $0.02 earnings per share was revealed for previous quarter. Ticker’s shares touched $26.51 during the last trading session after 0.67% change.Currently CytomX Therapeutics, Inc. is uptrending after 66.04% change in last May 3, 2017. CTMX has also 151,017 shares volume. CTMX outperformed by 54.49% the S&P500.

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical firm in the United States.The company has $1.03 billion market cap. The firm develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166.Currently it has negative earnings. The Company’s other product candidates in preclinical development include CX-2029, CD71, CTLA-4, and CX-188.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.